A case of apathy due to frontotemporal dementia responsive to memantine.
To study the effect of memantine on apathy, a common symptom of behavioral variant frontotemporal dementia (bvFTD). The patient underwent an off-label trial of memantine with behavioral inventories and [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) scans performed at baseline, 7 weeks and 6 months. The patient was a 66-year-old male whose main manifestation of bvFTD was affective, behavioral and cognitive apathy. The patient began memantine at an oral dose of 5 mg per morning and titrated up by 5 mg per week to the maintenance dose of 10 mg PO bid. Informants reported reduction of the apathy. The insula and cerebellum, both involved in the salience network, showed improved metabolism. Further study to correlate the effects of memantine on apathy and the salience network in bvFTD are warranted.